User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

EANM procedure guidelines for PET brain imaging using [(18)F]FDG : version 2

Primary tabs

Varrone, Andrea Asenbaum, Susanne Vander Borght, Thierry [UCL] Booij, Jan Nobili, Flavio Van Laere, Koen [KUL]

These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting the results of fluorine-18 fluoro-2-deoxyglucose ([(18)F]FDG) PET imaging of the brain. The aim is to help achieve a high standard of FDG imaging, which will increase the diagnostic impact of this technique in neurological and psychiatric practice. The present document replaces a former version of the guidelines that were published in 2002 [1] and includes an update in the light of advances in PET technology, the introduction of hybrid PET/CT systems and the broadening clinical indications for FDG brain imaging. These guidelines are intended to present information specifically adapted for European practice. The information provided should be taken in the context of local conditions and regulations.

Document type Article de périodique (Journal article) – Article de recherche – Journal Article
Access type Accès restreint
Publication date 2009
Language Anglais
Journal information "European Journal of Nuclear Medicine and Molecular Imaging" - Vol. 36, no. 12, p. 2103-2110 (2009)
Peer reviewed yes
Publisher Springer ((Germany) Heidelberg)
issn 1619-7070
e-issn 1619-7089
Publication status Publié
Affiliation UCL - (MGD) Service de médecine nucléaire
MESH Subject Societies ; Research Report ; Pregnancy ; Positron-Emission Tomography - adverse effects - contraindications - methods ; Patient Care Management ; Image Interpretation, Computer-Assisted ; Humans ; Fluorodeoxyglucose F18 - adverse effects - contraindications - diagnostic use ; Female ; Europe ; Child ; Brain - radionuclide imaging ; Adult
Keywords Glucose ; Metabolism ; PET ; Dementia ; Oncology ; Epilepsy ; Movement disorders
Links
  1. Bartenstein P, Asenbaum S, Catafau A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging 2002;29:BP43–8.
  2. Kuwert T, Bartenstein P, Grünwald F, et al. Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference. Nervenarzt 1989;69:1045–160.
  3. Asenbaum S. Guideline for the use of FDG PET in Neurology and Psychiatry. Austrian Society of Nuclear Medicine 2001. http://www.ogn.at .
  4. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302–5.
  5. Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med 1996;37:1256–9.
  6. Messa C, Fazio F, Costa DC, Ell PJ. Clinical brain radionuclide imaging. Semin Nucl Med 1995;25:111–43.
  7. Setani K, Schreckenberger M, Sabri O, et al. Comparison of different methods for attenuation correction in brain PET: effect on the calculation of the metabolic rate of glucose. Nuklearmedizin 2000;39:50–5.
  8. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.
  9. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160–7.
  10. Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 2008;49:390–8.
  11. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46.
  12. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.
  13. Henry TR, Votaw JR. The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am 2004;14:517–35.
  14. Van Paesschen W, Dupont P, Sunaert S, Goffin K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol 2007;20:194–202.
  15. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.
  16. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008;5:727–33.
  17. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915–21.
  18. Cranston I, Marsden P, Matyka K, et al. Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab 1998;18:130–40.
  19. Spanaki M. V., Siegel H., Kopylev L., Fazilat S., Dean A., Liow K., Ben-Menachem E., Gaillard W. D., Theodore W. H., The effect of vigabatrin ( -vinyl GABA) on cerebral blood flow and metabolism, 10.1212/wnl.53.7.1518
  20. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson´s disease studied in the off and on conditions with [18F]FDG-PET. Mov Disord 2001;6:1014–22.
  21. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., Eidelberg D., Metabolic correlates of levodopa response in Parkinson's disease, 10.1212/wnl.57.11.2083
  22. Ruotsalainen U, Suhonen-Polvi H, Eronen E, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996;37:387–93.
  23. Wu T-H, Huang Y-H, Lee JJS, Wang S-Y, Wang S-C, Su C-T, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging 2004;31:38–43.
  24. Chen WP, Matsunari I, Noda A, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med 2005;46:1633–41.
  25. Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissue: theoretical considerations and practical procedure. J Nucl Med 1993;34:360–9.
  26. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661–81.
  27. Henry TR, Engel J Jr, Mazziotta JC. Clinical evaluation of interictal fluorine-18-fluordeoxyglucose PET in partial epilepsy. J Nucl Med 1993;34:1892–998.
  28. Schreckenberger M, Spetzger U, Sabri O, et al. Localisation of motor areas in brain tumour patients: a comparison of preoperative 18-FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med 2001;28:1394–403.
  29. Herholz K, Pietrzyk U, Karbe H, et al. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett 1994;182:47–50.
  30. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993;34:322–9.
  31. Graham MM, Muzi M, Spence AM, et al. The FDG lumped constant in normal human brain. J Nucl Med 2002;43:1157–66.
  32. Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.
  33. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human brain function. London: Academic Press; 1997.
  34. Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG-PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999;40:737–46.
  35. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–78.
Bibliographic reference Varrone, Andrea ; Asenbaum, Susanne ; Vander Borght, Thierry ; Booij, Jan ; Nobili, Flavio ; et. al. EANM procedure guidelines for PET brain imaging using [(18)F]FDG : version 2. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, no. 12, p. 2103-2110 (2009)
Permanent URL http://hdl.handle.net/2078.1/29643